Work

A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)

Year: 2014

Type: conference-abstract

Abstract: Meeting abstracts A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with metastatic pancreatic adenocarcinoma (PDA). GVAX is composed of lethally-irradiated, allogeneic pancreatic cancer cells modified to express GM-CSF and

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p68

Authors: Andrea Wang-Gillam, Vincent Picozzi, Todd Crocenzi, Michael Morse, Herbert Zeh, Robert Fine, Aimee Murphy, Justin Skoble, Edward Lemmens, Sandy Ferber, Allan Rosen, John Grous, Thomas W Dubensky, Dirk Brockstedt, Elizabeth Jaffee, Dung Le

Institutions: Washington University in St. Louis, Virginia Mason Medical Center, Duke Medical Center, University of Pittsburgh Medical Center, Columbia University, Aduro BioTech (United States), Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W1980922191

Cites:

Cited by: 1

Related to: 10